These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18056271)

  • 21. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
    Arvieux C; Tribut O
    Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients.
    Barbour AM; Gibiansky L; Wire MB
    J Clin Pharmacol; 2014 Feb; 54(2):206-14. PubMed ID: 25272370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
    J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers.
    Sadler BM; Piliero PJ; Preston SL; Lloyd PP; Lou Y; Stein DS
    AIDS; 2001 May; 15(8):1009-18. PubMed ID: 11399983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.
    Boffito M; Dickinson L; Hill A; Back D; Moyle G; Nelson M; Higgs C; Fletcher C; Gazzard B; Pozniak A
    J Acquir Immune Defic Syndr; 2004 Nov; 37(3):1376-84. PubMed ID: 15483467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial.
    Cohen C; Dejesus E; Lamarca A; Young B; Yau L; Patel L; Vavro C; Wire MB; Wannamaker P; Shaefer M
    HIV Clin Trials; 2010; 11(5):239-47. PubMed ID: 21126954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients.
    Goujard C; Vincent I; Meynard JL; Choudet N; Bollens D; Rousseau C; Demarles D; Gillotin C; Bidault R; Taburet AM
    Antimicrob Agents Chemother; 2003 Jan; 47(1):118-23. PubMed ID: 12499178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
    Cao YJ; Smith PF; Wire MB; Lou Y; Lancaster CT; Causon RC; Bigelow GE; Martinez E; Fuchs EJ; Radebaugh C; McCabe S; Hendrix CW
    Pharmacotherapy; 2008 Jul; 28(7):863-74. PubMed ID: 18576901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.
    Wire MB; Shelton MJ; Studenberg S
    Clin Pharmacokinet; 2006; 45(2):137-68. PubMed ID: 16485915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
    McRae M; Clay PG; Anderson PL; Glaros AG
    Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.
    Zhu L; Hruska M; Hwang C; Shah V; Furlong M; Hanna GJ; Bertz R; Landry IS
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3816-22. PubMed ID: 25870057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers.
    la Porte CJ; Sabo JP; Elgadi M; Cameron DW
    Antimicrob Agents Chemother; 2009 Jan; 53(1):162-73. PubMed ID: 19015362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children.
    Fortuny C; Duiculescu D; Cheng K; Garges HP; Cotton M; Tamarirt DP; Ford SL; Wire MB; Givens N; Ross LL; Lou Y; Perger T; Sievers J
    Pediatr Infect Dis J; 2014 Jan; 33(1):50-6. PubMed ID: 23811744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV.
    Collier AC; Tierney C; Downey GF; Eshleman SH; Kashuba A; Klingman K; Vergis EN; Pakes GE; Rooney JF; Rinehart A; Mellors JW;
    HIV Clin Trials; 2008; 9(2):91-102. PubMed ID: 18474494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
    Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin.
    Busti AJ; Bain AM; Hall RG; Bedimo RG; Leff RD; Meek C; Mehvar R
    J Cardiovasc Pharmacol; 2008 Jun; 51(6):605-10. PubMed ID: 18520949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
    Luber AD; Brower R; Kim D; Silverman R; Peloquin CA; Frank I
    HIV Med; 2007 Oct; 8(7):457-64. PubMed ID: 17760738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.
    Wood R; Arasteh K; Stellbrink HJ; Teofilo E; Raffi F; Pollard RB; Eron J; Yeo J; Millard J; Wire MB; Naderer OJ
    Antimicrob Agents Chemother; 2004 Jan; 48(1):116-23. PubMed ID: 14693528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy.
    Cespedes MS; Castor D; Ford SL; Lee D; Lou Y; Pakes GE; Aberg JA
    J Acquir Immune Defic Syndr; 2013 Apr; 62(5):550-4. PubMed ID: 23314414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir.
    Gruber VA; Rainey PM; Moody DE; Morse GD; Ma Q; Prathikanti S; Pade PA; Alvanzo AA; McCance-Katz EF
    Clin Infect Dis; 2012 Feb; 54(3):414-23. PubMed ID: 22100576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.